Economic Impact

The high cost of sepsis

Sepsis is a leading cause of death and is one of the top drivers of healthcare costs globally.1,2 Consider this:

  • The prevalence in the U.S. alone conservatively exceeds 1.6 million cases per year, resulting in approximately 500,000 deaths.3
  • In 2015, sepsis accounted for $23.7 billion in payer costs, making it the most expensive disease in the U.S. hospital system.4
  • The UK sees 147,000 cases diagnosed each year, contributing to 42,000 deaths5 and £2 billion in sepsis-related costs.6 It is the country's #2 killer after cardiovascular disease and claims more lives than lung cancer annually.7

With healthcare systems under ever-increasing cost management pressures, tackling sepsis-related expenses is a major priority for most providers. The T2Sepsis Solution™ can reduce sepsis-related costs by dramatically reducing patient length of stay and antimicrobial drug costs.

Proven return on investment with the T2Candida Panel

Candida infections, which are disproportionately deadly and costly to treat, can have a significant impact on the economics of a hospital system, even when incidence is relatively low. In the U.S., a typical patient with a Candida infection stays an average of 40 days in the hospital,8 including 9 days in the ICU,9 resulting in an average cost per hospital stay of over $130,000 per patient.8

Use of the T2Candida Panel enables hospitals to detect Candida infections in hours—not days—thus allowing clinicians to get the right treatment to the patient much more rapidly. In a study published in the American Journal of Respiratory and Critical Care Medicine, providing targeted antifungal therapy within 24 hours of the presentation of symptoms:

  • Decreased the length of hospital stay by approximately 9 days.10
  • Decreased the average cost of care by approximately $30,000 per patient.10

In addition, many hospitals initiate antifungal drugs while waiting for blood-culture-based diagnostic results. This practice is currently in use with, on average, more than 40% of high-risk patients—and for all high-risk patients in some hospitals. A negative result from the T2Candida Panel provides timely data that can help physicians avoid unnecessary antifungal treatment and potentially reduce the treatment costs by $500 or more per patient.11 The overall economic impact of T2Candida for a given hospital system is $27,000 saved per infected patient and up to an additional $500 per patient in savings due to reduction in empiric therapy.11

Routine clinical use of the T2Candida Panel have confirmed these modeled findings and have demonstrated that the T2Candida Panel can deliver a 5X return on investment—or more:

  1. Henry Ford Hospital (Detroit, MI, USA) reduced the median ICU length of stay per patient by 7 days and showed a trend in reducing total LOS by an average of 4 days per patient.  The hospital was also able to reduce or discontinue antifungal therapy. These factors were seen as major contributors to a projected $2.3 million in annual savings.12
  2. Lee Health System (Ft. Myers, FL, USA) realized length-of-stay savings of 7 days for positive patients and captured about $200 in savings per negative patient by rapidly discontinuing or de-escalating antifungal drug therapy.13
  3. Huntsville Hospital (Huntsville, AL, USA) projected gross pharmacy savings of about $500 per patient tested as a result of rapid discontinuation and de-escalation of antifungal therapy.14

Rapid diagnosis can save lives

In a recent study published in Future Microbiology, early detection of Candida species identification allowed for timely, accurate treatment as necessary—and helped hospitals avoid unnecessary treatment when results were negative. Rapid detection also demonstrated a reduction of 60.6% Candida-related deaths per hospital.11


1. Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA. 2014;312:90–92.
2. Fleischmann C, Scherag A, Adhikari NK, et al.; International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193:259–272.
3. Elixhauser, A., Friedman, B., Stranges, E. (2011). Statistical Brief# 122. Healthcare Cost and Utilization Project (HCUP). October.
4. HCUP Statistical Brief #204. May 2016. Agency for Healthcare Research and Quality, Rockville, MD.
5. Hex, Nick et al. The Cost of Sepsis Care in the UK. 2017.
6. Vincent, J., et al. “Sepsis in European intensive care units: results of the SOAP study.” Critical Care Medicine-Baltimore. 34.2 (2006): 344.
7. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist’s perspective). Journal of Antimicrobial Chemotherapy. 2011 Apr 1;66(suppl 2):ii11-23.
8. Gagne, J. J., Breitbart, R. E., Maio, V., et al. (2006). Costs associated with candidemia in a hospital setting. P and T, 31(10), 586.
9. Morrell, M., Fraser, V. J., and Kollef, M. H. (2005). Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy, 49(9), 3640-3645.
10. Arnold, H. M., Micek, S. T., Shorr, A. F., et al. (2010). Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy: the journal of human pharmacology and drug therapy, 30(4), 361-368 1
11. Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., and Munakata, J. (2015). The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future microbiology, (10) 7,1133-1144.
12. Wilson, N.M., Kenney, R.M.,  Tibbetts, R.J., et. al.  T2 Magnetic Resonance Improves the Timely Management of Candidemia. Poster Presentation IDWeek 2016.
13. Estrada, S. J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.
14. Kateon H et al. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital. Poster Presentation IDWeek 2016.